MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
DEL-22379
CAS No. : 181223-80-3
MCE 国际站：DEL-22379
产品活性：DEL-22379 是一种 ERK 二聚化抑制剂。DEL-22379 易与 ERK2 结合，Kd 为低微摩尔水平，即使在低纳摩尔浓度下也可检测到 EL-22379 与 ERK2 结合。DEL-22379 抑制 ERK2 二聚化，IC50 约为 0.5 μM。
研究领域：MAPK/ERK Pathway | Stem Cell/Wnt | Apoptosis
In Vitro: DEL-22379 is an ERK dimerization inhibitor. DEL-22379 abolishes EGF-induced co-immunoprecipitation of ectopic ERK2 molecules tagged with hemagglutinin (HA) or FLAG epitopes, with an estimated half-maximal inhibitory concentration (IC50) of ~0.5 μM. DEL-22379 inhibits growth of tumor cells harboring RAS-ERK pathway oncogenes. The biological effects of DEL-22379 are investigated on tumor cells in culture. The cytostatic effects of DEL-22379 are compared to those of the MEK inhibitor PD-0325901 and the ERK kinase inhibitor SCH-772984, as reflected by their half-maximal growth inhibitory concentrations (GI50). Cell lines harboring mutant BRAF are the most sensitive to the three compounds. In comparison, wild-type (WT) cell lines for BRAF and RAS are the most resistant, and RAS mutant cells exhibit a range of sensitivities. In cells showing different oncogenic genotypes, distinct sensitivity to DEL-22379 can not be attributed to variations on its effects on dimerization, because DEL-22379 displays similar dimerization- and cytoplasmic signaling-inhibitory dose responses (IC50 of 150-400 nM) regardless of the genotype.
In Vivo: To test DEL-22379 antitumor effects, some of the aforementioned cell lines are xenografted into nude mice, and tumor growth is monitored after intra-peritoneal administration of DEL-22379 at 15 mg/kg. At such a dose, inhibition of ERK dimerization is evident in liver extracts and in xenografted tumors. DEL-22379 markedly inhibits tumor progression for A375 cells (BRAF mutant).
相关产品：Bioactive Compound Library Plus | Apoptosis Compound Library | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Stem Cell Signaling Compound Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Glutamine Metabolism Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Pain-Related Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | Serine/Threonine Kinase Inhibitor Library | Bioactive Compound Library Max | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | Paclitaxel | Z-VAD-FMK | LY294002 | 2-Deoxy-D-glucose | Angiotensin II human | Acetylcysteine | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Oxaliplatin | Deferoxamine mesylate | Sorafenib | Trametinib | Gemcitabine | Temozolomide | Etoposide | Rotenone | Mdivi-1 | Monomethyl auristatin E | Decitabine | Ruxolitinib | Elesclomol | DAPT
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
